Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world.
  • Posted by Rachel Arthurs
  • July 1, 2019
  • Blogs

Living with rheumatoid arthritis: How social stigma, unemployment and the rise of mental illness affects patient attitudes toward their disease in Japan

Living with rheumatoid arthritis: How social stigma, unemployment and  the rise of mental illness affects patient attitudes toward  their disease in Japan

Rachel Arthurs explores differing social attitudes towards RA between patients living in Japan and patients in Europe and Canada.

In recent months, Research Partnership’s Mariel Metcalfe alongside her Living With team have been conducting an in-depth multi-country study into the experiences of those living with rheumatoid arthritis. The study was carried out amongst patients in Europe, Canada and Japan to gain insights into the ways in which patients react to their diagnosis, manage their treatment and the possible support they hope to see in the future. An interesting trend that emerged during the course of the research was the differing social attitudes towards illness between patients living in Japan compared to those in Europe and Canada. Japanese patient’s daily lives are impacted differently to those in other countries, possibly due to pre-existing stigmas and social attitudes. In this article, we examine these differences, consider why they might occur and propose how we can use this understanding to improve global treatment solutions and marketing of existing and pipeline pharmaceuticals.

read more »

  • Posted by Liza Pliss and Lydia Gau
  • June 28, 2019
  • Webinars

Usability and UX: You’ve been asked to test… what next?

Usability and UX: You’ve been asked to test… what next?

The healthcare industry is increasingly using digital channels to deliver information and services to its customers. However, for these to be effective and increase brand satisfaction, it’s critical that patients, HCPs, and any other stakeholders have a positive user experience.
 

read more »

  • Posted by Misti Paul & Will Tolley
  • June 25, 2019
  • Webinars

MRX time machine: How to use time series forecasting to improve your demand assessment

MRX time machine: How to use time series forecasting to improve your demand assessment

In the second part of our Innovation in #MRX series we demonstrate how to use time series forecasting to better inform product uptake and competitive scenarios up to 10 years into the future.

Understanding likely demand for a new product or service is essential to help develop the right brand strategy. Techniques such as conjoint and fixed product profile assessments are great for evaluating the market landscape and opportunity, but are they enough? Can we predict the future with greater accuracy? Time series forecasting is one of the latest market research innovations we have been championing at Research Partnership and we would like to share the benefits of this technique with you. 

read more »

How patient insights were brought to life with graphic novel outputs

How patient insights were brought to life with graphic novel outputs

Our client was developing a novel therapy for the treatment of a rare disease in which patients suffer acute symptomatic attacks. Their new product promised greater freedom from these acute attacks and therefore from the associated burden. The challenge was to understand why many patients remain on older therapy types and how the pathway to more modern therapy options, with better efficacy and side effect profiles, could be mapped out for physicians and patients. Our client further requested that insights from the research were brought to life in the insights workshop meeting in a new and impactful way.
 

read more »

  • Posted by Dr. Chris Gaj
  • June 25, 2019
  • Articles

The Promise and Pitfalls of Molecular Testing in Oncology

 The Promise and Pitfalls of Molecular Testing in Oncology

Dr. Chris Gaj explores the challenges and potential consequences for stakeholders in the US, Europe and emerging markets in the latest issue of pharmaphorum's Deep Dive (Published June 2019).

Early targeted therapies, such as the tyrosine kinase inhibitor erlotinib from Roche/Genentech/OSI, offered the promise of precision medicine to treat cancer at a molecular level. Oncologists noted individual “Lazarus-like” responses to erlotinib, but overall effectiveness was moderate in unselected populations. It was not until the discovery that specific activating mutations in the epidermal growth factor receptor (EGFr) conveyed sensitivity to erlotinib that oncologists could identify the patients most likely to respond and target them for treatment while limiting exposure to those unlikely to respond.

read more »